Lay summaries have become an established component of modern clinical research communications, serving both regulatory and ethical purposes. Beyond compliance obligations, they support transparency, strengthen public trust in research, and provide participants with accessible explanations of study outcomes.
Under the EU Clinical Trial Regulation (CTR; EU No 536/2014), sponsors are required to publish plain-language summaries of clinical trial results in the local language(s) of countries where trials were conducted. As expectations around transparency and participant engagement continue to evolve, lay summaries are increasingly viewed not simply as a disclosure requirement, but as an important interface between sponsors, participants, and the wider public.
This article outlines the regulatory framework governing lay summaries, examines current expectations for accessibility and readability, and explores how sponsors can develop summaries that support both compliance and effective stakeholder communication.
Contents
The Strategic Role of Lay Summaries in Clinical Research
Lay summaries provide a non-technical overview of a clinical trial’s objectives, methodology, and findings for participants and non-specialist audiences. Their purpose is not to replicate the level of detail contained in clinical study reports or scientific abstracts, but to communicate key outcomes in a form that is accessible, accurate, and contextually meaningful.
In contrast to scientific publications intended for regulators, clinicians, and researchers, lay summaries are specifically designed for readability and comprehension by participants and other non-specialist audiences, rather than technical depth. Regulatory guidance, including the EU document “Summaries of Clinical Trial Results for Laypersons”, establishes expectations around clarity, structure, translation quality, and presentation.
Current guidance emphasizes several core principles:
- Include the trial identifiers and a short plain title so readers can find the full record.
- Ensure each summary is concise and accessible to readers aged 12 and older.
- Use absolute numbers alongside percentages and avoid unexplained statistical jargon.
- Encourage simple visuals, such as infographics or labeled charts, to aid understanding.
- Where feasible, test the draft with a small number of people from the target audience.
- Provide the lay summary in the local language(s) of each country where the trial ran, and take care to preserve meaning.
Regulatory Expectations for Clinical Trial Lay Summaries
Under the EU Clinical Trial Regulation, preparing and publishing a plain-language (lay) summary of clinical trial results is a legal requirement for trials conducted within the EU/EEA. Sponsors must submit the lay summary (alongside the technical results) to the central Clinical Trials Information System (CTIS) database and meet the expectations for submission and publication.
Importantly, the CTR requires that completed lay summaries are “to be provided in the local language of each of the EU countries where the trial took place,” so sponsors should plan for multilingual production and localization as part of their results reporting workflow. Furthermore, it is stated that “translated summaries should also take into account the cultural validity of the medical or technical terminology used.” Achieving this requires specialist life sciences language expertise to ensure terminology and context are accurate, appropriate, and understood by local audiences.
That being said, enforcement and implementation have not been uniform across all nations. The regulation is directly applicable in EU member states (and the EEA), but some countries have been more proactive in enforcing lay-summary rules, while others have been slower to apply meaningful enforcement in practice. Sponsors should therefore assume the full regulatory burden and build those tasks into study timelines to avoid local compliance gaps or delays.
Why Lay Summaries Matter for Sponsors and Trial Success
There are several reasons why lay summaries have become central to the success of clinical trials:
Respect & Reciprocity to Participants
Returning results in plain language honors participants’ contributions and fulfills an ethical obligation. Volunteers give time to advance science, and lay summaries are a direct, respectful way to show what their participation achieved.
Transparency & Public Trust
Clear and accessible summaries make the research process more open and understandable, which builds confidence in clinical research and the sponsor. Transparency reduces suspicion and counters misinformation by showing methods, results, and limitations in a nontechnical way.
Recruitment & Retention Value
When patients and advocacy groups see that results are shared plainly and promptly, they’re more likely to join future trials and stay engaged. Demonstrating a track record of returning results can become a recruitment asset for sites and sponsors.
Reputation & Communications
Well-written lay summaries are shareable patient-facing assets for medical affairs, patient engagement teams, and corporate communications. They help sponsors tell a balanced story about impact and safety without overpromising, supporting relations with regulators, clinicians, patients, and the broader media.
Risk Mitigation
Plain summaries reduce the chance of misinterpretation and regulatory or reputational fallout. By explaining benefits and risks clearly (using absolute numbers and context), sponsors lower the risk of misunderstanding that can lead to mistrust or inappropriate off-label use discussions.
Building an Effective Lay Summary Review Process
The lead author for a lay summary should be an experienced medical writer with a strong understanding of clinical research and a proven ability to translate complex scientific information into plain language. The writer must balance accuracy with accessibility, ensuring the summary is understandable to a nontechnical audience while remaining fully aligned with the underlying clinical data.
Effective lay summaries are rarely produced in isolation. Input should be gathered from a range of relevant staff, including:
- Chief investigators (to confirm scientific accuracy)
- Legal and regulatory experts (to ensure compliance with the relevant regulatory authority)
- Medical affairs teams (to align interpretation of results and messaging)
- Patient reviewers or patient advocacy representatives (to test clarity and usefulness from a real-world perspective)
Strong governance supports high-quality delivery. Sponsors should implement clear version control, define a sign-off matrix with named approvers across functions, and agree on a target turnaround time that fits within regulatory submission deadlines. Establishing this framework early in the trial lifecycle helps avoid last-minute delays and compliance risks.
How Conversis Can Help
At Conversis, an IQVIA business, our specialists balance scientific accuracy with clear, accessible language, ensuring your lay summaries are easy to understand for every intended audience. Get in touch with us today to find out more about how we can support you.
Maximizing the Value of Lay Summaries Across Clinical Trials
How can you derive the most value from a lay summary? Let’s take a look at the most important aspects to consider:
Strategy & Planning
Build lay-summary work into the trial timeline from the protocol stage onward rather than leaving it to the end. Treat the lay summary as both a compliance deliverable and a patient-facing communications asset; define who will own it, budget for translation and PPI (patient and public involvement), and schedule sign-offs so the summary meets regulatory deadlines without last-minute rushes.
Content & Structure
Always include trial identifiers and a plain title, a one-line purpose, who took part, what was tested, the main results, safety/side-effects, and a clear “what this means” for patients. When presenting results, show absolute numbers alongside percentages (for example, “20 of 100 participants (20%)”) to minimize confusion and avoid unexplained statistical jargon.
Language & Localization
Aim for plain language and short sentences, avoiding unexplained jargon and long clauses. Importantly, regulations like the CTR make translation a regulatory obligation: completed lay summaries must be translated into every language in which the clinical trial took place. This obligation should shape your operational planning.
Identify required target languages at the protocol stage, budget for professional medical translation and review, and schedule translation and localization tasks into your timeline rather than leaving them to the end.
Format & Accessibility
Design for readability using white space, clear headings, bullets, and short paragraphs so readers can scan easily. Consider alternative formats, such as short videos, audio summaries, or comic-style explanations for pediatric studies to reach different audiences. You should always provide HTML/text versions suitable for screen readers and text-to-speech tools.
Review, Authorship, & Governance
Assign a lead medical writer to draft the summary, supported by named reviewers: the principal investigator for clinical accuracy, a biostatistician for numbers, regulatory/legal for compliance, and patient reviewers for clarity and tone. Maintain version control and a clear sign-off matrix, and agree on target turnaround times so the lay summary is ready for submission and publication on schedule.
Dissemination & Relationships
Deliver results through sites and investigators where the participant relationship is strongest; these sites are often the best channel for personal follow-up. Publish to registries/CTIS as required and host the summary on sponsor trial pages and site portals. Avoid using lay summaries as promotional material, as they must remain balanced, accurate, and not cherry-pick favorable findings.
Ensuring Accuracy and Consistency Across Global Trials
For global trials, accuracy and accessibility depend on more than direct translation. Sponsors should work with experienced language service providers (LSPs) like Conversis to produce lay summaries that are not only linguistically accurate but also culturally and contextually appropriate for each target audience.
By combining specialist medical writers, subject-matter expertise, and structured quality assurance, Conversis can ensure that plain-language summaries remain faithful to the source data while meeting patient readability standards. This approach supports consistent messaging across markets, reduces the risk of misinterpretation, and enables sponsors to deliver compliant, localized lay summaries that are genuinely understood by participants wherever a trial takes place.
Supporting Global Clinical Trial Communications With Conversis
When it comes to communicating clinical trial results in terms that make linguistic and cultural sense to all audiences, the life science experts at Conversis, an IQVIA business, are ready to help!
We use our clinical and regulatory knowledge to ensure all lay summaries preserve meaning whilst remaining easy to understand. If you’d like to learn more about how we can support your organization, please get in touch with our team today.
Contact our experts
